Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/04/2012US20120251617 Bi-functional shrna targeting stathmin 1 and uses thereof
10/04/2012US20120251616 Tocopherols, Tocotrienols, Other Chroman and Side Chain Derivatives and Uses Thereof
10/04/2012US20120251615 Agent for intra-articular injection
10/04/2012US20120251613 Method for treating vitiligo with a prostaglandin analogue
10/04/2012US20120251612 Wound Healing Device, Method for Making the Same and Method for Treating a Wound
10/04/2012US20120251610 Nicotine-containing patch preparation
10/04/2012US20120251607 Antimicrobial compositions, methods of preparation thereof, and uses thereof
10/04/2012US20120251596 Nanoemulsion, method for its preparation and use
10/04/2012US20120251595 Emulsion template method to form small particles of hydrophobic agents with surface enriched hydrophilicity by ultra rapid freezing
10/04/2012US20120251594 Delivery of Submicrometer and Nanometer Aerosols to the Lungs Using Hygroscopic Excipients or Dual Stream Nasal Delivery
10/04/2012US20120251590 Controlled release formulations of opioid and nonopioid analgesics
10/04/2012US20120251588 Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
10/04/2012US20120251585 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
10/04/2012US20120251579 Compositions for generating an antigen specific immune response
10/04/2012US20120251571 Rnase l-mediated cleavage products and uses thereof
10/04/2012US20120251566 Saponin adjuvant compositions and methods relating thereto
10/04/2012US20120251562 Inhibitors of the PP1/GADD34 Complex for the Treatment of a Condition Requiring an Immunosuppressive Activity
10/04/2012US20120251560 Conjugated lipomers and uses thereof
10/04/2012US20120251551 Substituted (Heteroarylmethyl)thiohydantoins
10/04/2012US20120251545 Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90
10/04/2012US20120251543 Methods and compositions for modulating apoptosis
10/04/2012US20120251536 Biopolymer hybrid gel-depot delivery system
10/04/2012US20120251525 Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
10/04/2012US20120251523 Methods of Modulating TGFbeta Signaling
10/04/2012US20120251522 Targeted delivery of therapeutic agents with lyophilized matrices
10/04/2012US20120251514 Modulated programmed death ligand-1
10/04/2012US20120251510 Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
10/04/2012US20120251503 Methods of using chimeric coiled-coil molecule
10/04/2012US20120251502 Human Ebola Virus Species and Compositions and Methods Thereof
10/04/2012US20120251499 Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single cpg site in ttp promoter and treatment of cancers by regulating its epigenetic status
10/04/2012US20120251497 Inhibitors of hepatitis c virus
10/04/2012US20120251496 Ezatiostat for treating multiple myeloma
10/04/2012US20120251495 Pterin based therapies for inflammatory conditions
10/04/2012US20120251492 Triterpene derivative and agent for preventing or treating chronic hepatitis c
10/04/2012US20120251491 Fused tricyclic aryl compounds useful for the treatment of viral diseases
10/04/2012US20120251487 Compounds and pharmaceutical compositions for the treatment of viral infections
10/04/2012US20120251483 Infarction Treatment Compositions and Methods
10/04/2012US20120251482 Use for improving 5-ht function and enos expression of kmups amine salts
10/04/2012US20120251479 Reduced-Odor Polyol Composition And Method Of Producing Same
10/04/2012US20120251478 Method for treatment of a glomerular disease comprising administration of anion exchange resin
10/04/2012US20120251465 Flavor composition containing flavone glycosides
10/04/2012US20120251464 Chalcones as enhancer of antimicrobial agents
10/04/2012US20120251463 Nicotinamide Riboside Kinase Compositions and Methods for Using the Same
10/04/2012US20120251462 Agent For Smoker Dehabituation
10/04/2012US20120251461 [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy
10/04/2012US20120251457 Methods and compositions for modulating adipocyte function
10/04/2012US20120248142 Pharmaceutical composition
10/04/2012US20120247982 Stabilized pharmaceutical product
10/04/2012US20120247462 Antibiotic formulations, unit doses, kits, and methods
10/04/2012DE102011015567A1 Dosage forms, useful e.g. for the acute treatment of stress-induced pathologies in the central nervous system and cardiovascular system, comprise beta blockers, which are in the form of liquid aerosols
10/04/2012DE102011001768A1 Präparat oder Nahrungsergänzungsmittel Preparation, or dietary supplement
10/04/2012DE102004038535B4 Zelluläre Einschleusung von Nukleinsäurewirkstoffen Cellular introduction of nucleic acid drugs
10/04/2012CA2844699A1 Combinations of akt inhibitor compounds and abiraterone, and methods of use
10/04/2012CA2837122A1 Methods and compositions for enhancing the uptake of therapeutic agents by target cells
10/04/2012CA2833910A1 Carbonyl containing compounds for controlling and repelling cimicidae populations
10/04/2012CA2832066A1 Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage
10/04/2012CA2832050A1 Derivatives of sulindac, use thereof and preparation thereof
10/04/2012CA2831937A1 Combinations of akt inhibitor compounds and erlotinib, and methods of use
10/04/2012CA2831935A1 Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
10/04/2012CA2831932A1 Combinations of akt and mek inhibitor compounds, and methods of use
10/04/2012CA2831929A1 Pyrazolo pyrimidine derivatives
10/04/2012CA2831922A1 Combinations of akt inhibitor compounds and vemurafenib, and methods of use
10/04/2012CA2831915A1 Modulation of signal transducer and activator of transcription 3 (stat3) expression
10/04/2012CA2831848A1 Therapeutic treatment
10/04/2012CA2831822A1 Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
10/04/2012CA2831799A1 Novel oxazolidinone derivative and pharmaceutical composition including the same
10/04/2012CA2831771A1 Polyamide compound and pharmaceutical composition for treating mitochondrial genetic diseases
10/04/2012CA2831716A1 Compounds for treatment of metabolic syndrome
10/04/2012CA2831715A1 Pouch containing nicotine in free salt form
10/04/2012CA2831713A1 Bifunctional hydroxy-bisphosphonic acid derivatives
10/04/2012CA2831710A1 Substituted benzimidazoles as mps-1 kinase inhibitors
10/04/2012CA2831613A1 Delivery and formulation of engineered nucleic acids
10/04/2012CA2831612A1 Methods for treating cancer
10/04/2012CA2831600A1 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
10/04/2012CA2831590A1 (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
10/04/2012CA2831582A1 (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles , pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
10/04/2012CA2831566A1 Menthol liquids composition
10/04/2012CA2831548A1 Solid preparation
10/04/2012CA2831506A1 Compositions for the treatment of neurologic disorders
10/04/2012CA2831493A1 Thieno [2, 3 -d]pyrimidine derivatives and their use to treat arrhythmia
10/04/2012CA2831429A1 Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma- glutamyl-l-tryptophan
10/04/2012CA2831428A1 Alisporivir to treat hepatitis c virus infection
10/04/2012CA2831426A1 Methods for increasing efficacy of folr1 cancer therapy
10/04/2012CA2831421A1 Novel cephalosporin derivatives and pharmaceutical compositions thereof
10/04/2012CA2831356A1 Imidazo [1,2-a]pyridine_compounds for use in therapy
10/04/2012CA2831308A1 Intranasal benzodiazepine pharmaceutical compositions
10/04/2012CA2831291A1 Methods of targeted treatment of frontotemporal lobar degeneration
10/04/2012CA2831284A1 Compositions and methods for inhibiting expression of tmprss6 gene
10/04/2012CA2831218A1 Controlled release pharmaceutical dosage forms
10/04/2012CA2831190A1 Trpm5 inhibitors support body weight reduction without reducing food intake
10/04/2012CA2831185A1 Composition comprising a diindolylmethane and a retinoid to treat a skin condition
10/04/2012CA2831146A1 Trpv1 antagonists
10/04/2012CA2831143A1 Cyclopropylamines as lsd1 inhibitors
10/04/2012CA2831101A1 Connective tissue monitoring, compositions for connective tissue treatment and methods for treating connective tissue
10/04/2012CA2831025A1 Pharmaceutical composition for preventing or treating macular degeneration
10/04/2012CA2831015A1 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
10/04/2012CA2830984A1 Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10
10/04/2012CA2830965A1 Benzoic acid salt of otamixaban
10/04/2012CA2830962A1 Otamixaban formulations with improved stability
10/04/2012CA2830948A1 Osmotic mediated release synthetic nanocarriers
1 ... 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 ... 7860